The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...

Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.

Using anticoagulation alone—and avoiding aspirin— appears to limit adverse events after left atrial appendage occlusion (LAAO) with the Watchman FLX device (Boston Scientific), an analysis of ...

Boston Scientific Corporation BSX shares are down on Monday as the company faces pressure following a significant clinical ...

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Atrial fibrillation (AF) is an increasingly common heart rhythm disorder that affects approximately 59 million people worldwide 1 and increases stroke risk by five times compared to people with a ...